Altimmune, Inc. (ALT)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Altimmune, Inc. (“Altimmune” or “the Company”) (NASDAQ: ALT). Investors who purchased Altimmune securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether Altimmune has violated federal securities laws.

Investigation Details:

Altimmune’s stock price has more than tripled since November, after the Company reported that data from a mid-stage study of pemvidutide, Altimmune’s GLP-1 agonist drug candidate, showed promise. Then, on February 13, 2024, Kerrisdale Capital published a short report alleging that “a deeper examination of Altimmune’s data reveals a drug with little chance of competing against either the approved incumbents or the other GLP-1 agonists progressing through clinical trials.” On this news, Altimmune’s stock price fell sharply during intraday trading on February 13, 2024.

What’s Next?

If you are aware of any facts relating to this investigation or purchased Altimmune securities, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.


Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Nathanson

332-239-2660 | [email protected]